Servier SA has agreed to acquire KER-0193, a novel oral small molecule modulator targeting BK channels for Fragile X Syndrome (FXS), from Kaerus Bioscience for up to $450 million. KER-0193 demonstrated safety and excellent pharmacokinetics in Phase I trials, along with biomarker evidence of brain activity normalization consistent with its proposed therapeutic effect. The acquisition strengthens Servier’s neurology pipeline by adding a rare disease candidate addressing the leading inherited cause of autism and intellectual disability. Preparations are underway for Phase II proof-of-concept studies in the US and Europe, with US orphan drug designation granted.